MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration,…
Respiratory
-
-
Paratek’s antibiotic succeeds in Phase IIb lung disease trial
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in…
-
Qnovia set to trial smoking cessation inhaler in the US
Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX…
-
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
-
Pipeline Moves: Investigator-led oncology cell therapy trial terminated
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
-
University of Dundee to lead trial of bronchiectasis therapies
The University of Dundee in the UK is set to lead a clinical trial investigating whether existing medications can effectively…
-
Trials to watch: Four biologics concluding pivotal COPD trials
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…
-
Armata completes Phase II Tailwind study enrollment in US
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
-
More endpoints met in Insmed’s Phase III brensocatib trial
US-based Insmed has shared more data from the Phase III ASPEN trial, showing that brensocatib also reduced the decline in…
-
Insmed stocks soar as Phase III lung disease drug exceeds expectations
Insmed’s stocks more than doubled after the company announced its lead-pipeline candidate brensocatib succeeded in a Phase III trial. The…
